Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Singapore’s CytoMed Plans to Start Investigator Initiated Trials in China of Novel T Cell Therapies

publication date: Dec 6, 2023

Singapore’s CytoMed announced plans to conduct Investigator Initiated Trials in China of its allogeneic gamma delta T cells as therapies for solid tumor cancers. The company will collaborate with CytoMed China, a Hong Kong company that (despite its name) is owned by third parties, to conduct the trials in Chongqing, loaning the company $1 million over three years to oversee the test. If the trials are successful, CytoMed will acquire the China operation. CytoMed was spun out from Singapore’s A*STAR to develop cell therapies based on gamma delta T cells and gamma delta Natural Killer T cells in-licensed from A*STAR. More details....

Stock Symbol: (NSDQ: GDTC)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here